Comparative effectiveness and safety of inclisiran versus evolocumab and alirocumab: a 180-day real-world study. [PDF]
BMC Cardiovasc DisordYao J, Sun Q, Liu D, Lin J, Wang W.
europepmc +1 more source
Longitudinal management and novel pharmacological interactions in a patient with HeFH, 21-OHD, and kawasaki disease: a 6-year clinical follow-up. [PDF]
Front Endocrinol (Lausanne)Zhang Y, Yuan X, Yang X, Chen R.
europepmc +1 more source
Inclisiran-induced LDL-cholesterol reduction with and without concomitant statin therapy: a real-world analysis. [PDF]
BMC Cardiovasc DisordSeidel M +6 more
europepmc +1 more source
Discovery of Cetaben as a Novel Antiviral Agent Against Porcine Epidemic Diarrhea Virus From a Cholesterol-Lowering Compound Library. [PDF]
Transbound Emerg DisLi Y +11 more
europepmc +1 more source
Little Evidence of Atherosclerosis in a Middle-aged Japanese Woman with Familial Hypercholesterolemia Carrying PCSK9 (p.Glu32Lys) and ABCG8 (p.Ile419Asn) Variants despite Elevated Lipoprotein (a) Levels. [PDF]
Intern MedAono K +4 more
europepmc +1 more source
Advanced therapy in familial hypercholesterolemia. [PDF]
Can Fam PhysicianGao E, Brunham LR, Goldman RD.
europepmc +1 more source
PCSK9 inhibitors patterns of use in France from nationwide repeated cross-sectional and cohort studies. [PDF]
Sci RepSingier A +5 more
europepmc +1 more source
Obicetrapib and lipoprotein(a) levels in patients at high cardiovascular risk: a pooled analysis of trials. [PDF]
Eur Heart JNicholls SJ +8 more
europepmc +1 more source
Association Between PCSK9 Inhibitor Use and Risk of Age-Related Macular Degeneration. [PDF]
Transl Vis Sci TechnolTsai CY +7 more
europepmc +1 more source
Lipid-Lowering Efficacy and Adverse Events of CETP Inhibitor Combination Therapy: A Systematic Review and Network Meta-Analysis. [PDF]
J Cardiovasc PharmacolGuo P, Yu X, Wei X, Xiong X, Jiang J.
europepmc +1 more source